annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION
Head and Neck Cancer
Location: E354b
CME credit: 3
Track(s): Head and Neck Cancer
Søren M. Bentzen, MD—Co-Chair
University of Wisconsin
A. Dimitrios Colevas, MD—Co-Chair
Stanford University
3:00 PM Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer
(MTC): A randomized, double-blind phase III trial (ZETA). (Abstract #5503)
S. A. Wells, B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin, M. Santoro,
E. Baudin, J. R. Vasselli, J. Read, M. Schlumberger
3:15 PM Phase II trial of sunitinib in medullary thyroid cancer (MTC). (Abstract #5504)
J. A. De Souza, N. Busaidy, A. Zimrin, T. Y. Seiwert, V. M. Villaflor, K. B. Poluru,
P. L. Reddy, J. Nam, E. E. Vokes, E. E. Cohen
3:30 PM Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with
chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected
squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5505)
K. J. Harrington, A. Berrier, M. Robinson, E. Remenar, M. Housset,
F. Hurtado de Mendoza, N. Compton, M. Lau, P. Legenne, R. Kumar
3:45 PM An open-label, randomized, phase III trial of zalutumumab, a human
monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in
patients with noncurable squamous cell carcinoma (SCCHN) of the head and
neck who have failed standard platinum-based chemotherapy (ZALUTE).
(Abstract #LBA5506)
J. H. Machiels, S. Subramanian, A. Ruzsa, G. Repassy, I. Lifrenko, A. Flygare, P.
Sorensen, E. Ehrnrooth, O. Baadsgaard, P. M. Clement
Discussion
4:00 PM A. Dimitrios Colevas, MD (Abstracts #5503–LBA5506)
Stanford University
4:15 PM A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and
neck carcinomas (HNC): Impact of radiation and cisplatin intensity on
outcome. (Abstract #5507)
K. Ang, Q. Zhang, R. H. Wheeler, D. I. Rosenthal, F. Nguyen-Tan, H. Kim, C. Lu,
R. S. Axelrod, C. I. Silverman, R. S. Weber
4:30 PM Postoperative accelerated radiotherapy (POPART) versus conventional
postoperative radiotherapy (CPORT) in squamous cell head and neck
cancer: A multicenter prospective randomized study of the Dutch Head and
Neck Cooperative Study Group. (Abstract #5508)
J. A. Langendijk, J. H. Kaanders, P. Doornaert, F. R. Burlage, P. L. van den Ende,
S. B. Oei, R. B. Keus, S. Nuyts, C. R. Leemans, C. H. Terhaard, Dutch Head and
Neck Cancer Research Group
Discussion
4:45 PM Søren M. Bentzen, MD (Abstracts #5507–5508)
University of Wisconsin
5:00 PM Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor
(HGF) in patients with head and neck squamous cell carcinoma (HNSCC)
treated with chemoradiation on a phase III trial. (Abstract #5509)
D. Rischin, R. Fisher, K. Oliner, R. J. Young, H. Cao, G. A. McArthur, L. J. Peters,
B. O’Sullivan, Q. Le
410